Brought to you by 
BI signs optogenetics deal with Circuit focused on metabolic disease
04 Sep 2015
Executive Summary
In a three-year deal, Boehringer Ingelheim GMBH and Circuit Therapeutics Inc. plan to identify drug candidates for obesity and related metabolic diseases.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com